Related Experiment Videos

Intraperitoneal vancomycin and ceftazidime in the treatment of CAPD peritonitis

H H Gray, S Goulding, S J Eykyn

    Clinical Nephrology
    |February 1, 1985
    PubMed

    Insights

    This study shows intraperitoneal vancomycin and ceftazidime effectively treat continuous ambulatory peritoneal dialysis (CAPD) peritonitis. The antibiotic combination is safe, easy for patients to administer, and achieves good clinical outcomes.

    Area of Science:

    • Nephrology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Peritonitis is a common complication in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    • Effective antibiotic treatment is crucial for managing CAPD peritonitis and preventing complications.

    Purpose of the Study:

    • To evaluate the safety and efficacy of intraperitoneal vancomycin and ceftazidime in treating CAPD peritonitis.
    • To assess antibiotic concentrations in serum and dialysate during treatment.

    Main Methods:

    • Retrospective analysis of 64 episodes of CAPD peritonitis treated with intraperitoneal vancomycin and ceftazidime.
    • Measurement of serum and dialysate antibiotic levels in 19 patients.
    • Microbiological analysis of dialysate cultures.

    Main Results:

    • The antibiotic combination was safe and easily administered by patients.
    • Dialysate cultures were sterile in 52% of cases; staphylococci were isolated in 30%.
    • Maximum serum vancomycin level recorded was 30 mg/L, with an infection rate of 2.22 episodes per patient-year in 1983.

    Conclusions:

    • Intraperitoneal vancomycin and ceftazidime represent a safe and effective treatment option for CAPD peritonitis.
    • The regimen is well-tolerated and can be self-administered by patients, improving adherence and outcomes.

    Related Concept Videos